1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 10 NOVEMBER 2014

Cancer Drug News 10 NOVEMBER 2014

  • November 2014
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Dendreon Unlikely To Find Buyer With Provenge's Underperformance
Industry Brief - Altor Initiates Development Of ALT-803 In r/r MM Supported By Phase II SBIR Grant
Industry Brief - AstraZeneca/Pharmacyclics/Janssen Enter Immuno-Oncology Clinical Trial Collaboration
Industry Brief - MorphoSys' MOR208 Gains FDA Fast Track Designation For DLBCL
Industry Trend Analysis - FDA ODAC Vote Against MM Drug Is A Bad Start To Novartis' New Oncology Focus
Industry Brief - Phase II Trial Of Cabozantinib/Erlotinib Shows Positive Top-Line Results
Industry Brief - BI Reports Positive Phase III Results For Afatinib In Asian NSCLC Patients With del19 Mutation
Industry Brief - Exelixis Achieves Enrolment Target In Cabozantinib Phase III MRCC Study
Industry Brief - Tivantinib Phase II Study Meets Primary Endpoint Of PFS In Metastatic PCA
Industry Brief - Myriad/AbbVie Sign Expanded Agreement For Tumor BRACAnalysis CDx
Industry Trend Analysis - Future Of Amgen's Trebananib In Question After Disappointing Overall Survival Results
Industry Brief - FDA Grants ODD To Merrimack's MM-141 For PC
Industry Brief - FDA Approves Cyramza+Paclitaxel Combination for Advanced/Metastatic GC
Industry Brief - European VHP Clearance For Celsion's ThermoDox Phase III HCC Study
Industry Brief - Provectus Submits PV-10 Phase III Melanoma Protocol To FDA
Industry Brief - Felicitex/Selvita Collaborate To Target Quiescent Cancers
Industry Trend Analysis - AstraZeneca Strengthens Immuno-Oncology Capabilities With Diagnostics Acquisition

Table Of Contents

Cancer Drug News 10 NOVEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.